Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) Revenue
Annual & quarterly revenue history · segment & region breakdown
VIR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsVir Biotechnology, Inc. trailing twelve-month (TTM) revenue is $0.07B, a decrease of 7.61% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | -$0.01B | -7.61% |
| 2024-12-31 | $0.07B | -$0.01B | -13.90% |
| 2023-12-31 | $0.09B | -$1.53B | -94.67% |
| 2022-12-31 | $1.62B | +$0.52B | +47.51% |
| 2021-12-31 | $1.10B | +$1.03B | +1528.99% |
| 2020-12-31 | $0.07B | +$0.07B | +9357.81% |
| 2019-12-31 | $0.00B | -$0.00B | -18.09% |
| 2018-12-31 | $0.00B | +$0.00B | +482.55% |
| 2017-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare VIR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Vir Biotechnology, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Vir Biotechnology, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Vir Biotechnology, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
VIR revenue · 4 questionsVIR's trailing twelve-month (TTM) revenue is $0.07B. That is a decrease of 7.61% year-over-year from $0.07B in FY2025.
▸ Source: FMP · Vir Biotechnology, Inc. SEC filings · GAAP · Vir Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026